Evidence map›Paper›PMID 20105183›Full record

ArticleBritish journal of pharmacology2010

Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands.

Jillian G Baker, Richard Middleton, Luke Adams, Lauren T May, Stephen J Briddon, Barrie Kellam, Stephen J Hill

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 92 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Fluorescent APurinergic signalling · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Chemical Probes for the Adenosine Receptors.Pharmaceuticals (Basel, Switzerland) · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Jillian G BakerInstitute of Cell Signalling, School of Biomedical Sciences, Medical School, University of Nottingham, Queen's Medical Centre, Nottingham, UK.
Richard Middleton
Luke Adams
Lauren T May
Stephen J Briddon
Barrie Kellam
Stephen J Hill
University of Nottingham · GBQueen's Medical Centre · GB

Funding

Biotechnology and Biological Sciences Research Council BB/D008522/1Biotechnology and Biological Sciences Research Council BB/D521581/1Medical Research Council G0800006Wellcome Trust
6 · The paper itself

Abstract

background and purposeThe introduction of fluorescence-based techniques, and in particular the development of fluorescent ligands, has allowed the study of G protein-coupled receptor pharmacology at the single cell and single molecule level. This study evaluated how the physicochemical nature of the linker and the fluorophore affected the pharmacological properties of fluorescent agonists and antagonists. EXPERIMENTAL APPROACH: Chinese hamster ovary cells stably expressing the human adenosine A(1) receptor and a cyclic 3',5' adenosine monophosphate response element-secreted placental alkaline phosphatase (CRE-SPAP) reporter gene, together with whole cell [(3)H]-8-cyclopentyl-1,3-dipropylxanthine (DPCPX) radioligand binding, were used to evaluate the pharmacological properties of a range of fluorescent ligands based on the antagonist xanthine amine congener (XAC) and the agonist 5' (N-ethylcarboxamido) adenosine (NECA). KEY

resultsDerivatives of NECA and XAC with different fluorophores, but equivalent linker length, showed significant differences in their binding properties to the adenosine A(1) receptor. The BODIPY 630/650 derivatives had the highest affinity. Linker length also affected the pharmacological properties, depending on the fluorophore used. Particularly in fluorescent agonists, higher agonist potency could be achieved with large or small linkers for dansyl and BODIPY 630/650 derivatives, respectively. CONCLUSIONS AND IMPLICATIONS: The pharmacology of a fluorescent ligand was critically influenced by both the fluorophore and the associated linker. Furthermore, our data strongly suggest that the physicochemical properties of the fluorophore/linker pairing determine where in the environment of the target receptor the fluorophore is placed, and this, together with the environmental sensitivity of the resulting fluorescence, may finally decide its utility as a fluorescent probe.

Indexed as

LigandsMicroscopy, ConfocalMolecular ImagingMolecular Probe TechniquesAdenosine-5'-(N-ethylcarboxamide)Alkaline PhosphataseAnimalsBoron CompoundsCHO CellsCricetinaeCricetulusCyclic AMPDansyl CompoundsFluorescent DyesGenes, ReporterGPI-Linked Proteins1,3-dipropyl-8-cyclopentylxanthine4,4-difluoro-4-bora-3a,4a-diaza-s-indacene8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthineAdenosine-5'-(N-ethylcarboxamide)Alkaline Phosphatasealkaline phosphatase, placentalBoron CompoundsCyclic AMPDansyl CompoundsFluorescent DyesGPI-Linked ProteinsIsoenzymesLigandsReceptor, Adenosine A1Xanthines

Identifiers

PMID20105183
PMCPMC2829203
OpenAlexW1592221939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.